Hims & Hers Health Are Falling Today: What's Going On?
Hims & Hers Health Are Falling Today: What's Going On?
Meanwhile, other GLP-1 drugs, including dulaglutide, semaglutide and liraglutide, remain in shortage. Despite some reports of product availability, the FDA has not yet resolved these shortages and is actively monitoring the situation.Hims & Hers Health, Inc. (NYSE:HIMS) are trading lower Thursday. The U.S. Food and Drug Administration issued a new decision about tirzepatide injection shortages. Here's what you need to know.
Hims & Hers Health, Inc. (纽交所:HIMS) 星期四的交易价格下跌。美国食品药品监督管理局就tirzepatide注射剂的短缺发布了新的决定。以下是您需要了解的内容。
What To Know: The FDA announced today that the shortage of tirzepatide injections, a GLP-1 medication, has been resolved. The shortage began in 2022 due to high demand and has ended as manufacturing capacity and product availability are sufficient to meet national demand. However, the FDA warned of potential localized supply chain disruptions as products are distributed to pharmacies.
需要了解的事项：FDA今天宣布tirzepatide注射剂，这种GLP-1药物的短缺问题已经解决。短缺始于2022年，主要由于需求量大，而现在制造能力和产品供应足以满足全国需求。然而，FDA警告在将产品分发到药房时可能会出现局部供应链中断的情况。
To avoid interruptions in treatment, the FDA is allowing compounders using tirzepatide to continue their activities temporarily. State-licensed pharmacies have until February 18, 2025, and outsourcing facilities until March 19, 2025, to comply with this grace period.
为了避免治疗中断，FDA允许使用tirzepatide的配药师暂时继续其活动。获得州许可的药房必须在2025年2月18日之前遵守，而外包设施则需在2025年3月19日之前合规，以享受这一宽限期。
Meanwhile, other GLP-1 drugs, including dulaglutide, semaglutide and liraglutide, remain in shortage. Despite some reports of product availability, the FDA has not yet resolved these shortages and is actively monitoring the situation.
与此同时，其他GLP-1药物，包括dulaglutide、semaglutide和liraglutide，仍然短缺。尽管有一些产品可用的报告，FDA尚未解决这些短缺，并正在积极监测情况。
This announcement follows the FDA's October 2024 decision that determined that the tirzepatide shortage was over. However, this was reevaluated after legal challenges. This updated decision confirms that the shortage is resolved.
这一声明是在FDA于2024年10月做出的决定之后，该决定认为tirzepatide的短缺问题已经结束。然而，在法律挑战之后，这一决定被重新评估。此次更新的决定确认短缺问题已经解决。
The news may influence investor sentiment, given the role of GLP-1 drugs in weight loss and diabetes treatment. Ongoing shortages of similar medications and regulatory updates could continue to affect market perspectives.
这条资讯可能会影响投资者情绪，因为GLP-1药物在减肥和糖尿病治疗中的作用。类似药物的持续短缺和监管更新可能会继续影响市场前景。
HIMS Price Action: Hims & Hers shares were down 13.40% at $24.67 at the time of writing according to Benzinga Pro.
HIMS价格动态：根据Benzinga Pro，目前Hims & Hers的股票下跌了13.40%，报价为24.67美元。
- Luigi Mangione Faces Extradition, Possible Federal Charges May Carry Death Penalty
- 路易吉·曼吉奥尼面临引渡，可能的联邦指控可能面临死刑。
Image Via Shutterstock.
图片来自Shutterstock。
译文内容由第三方软件翻译。
